ADIPOQ and familial pancreatic carcinoma: A nested case‐control study of five cohorts in the United States reported that higher circulating adiponectin concentrations were associated with lower pancreatic cancer risk (OR for highest vs compared with lowest quintile 0.66 [95% CI = 0.44‐0.97]),39 whereas a null result was found between adiponectin and pancreatic cancer in an analysis of the EPIC study.40